Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12263231 | 0.81 | HTT (0.32) | HTTHSD17B10DYRK1ALMNATSHR | |
| SCHEMBL23619725 | 0.81 | AAK1 (0.32) | HTTHSD17B10DYRK1ALMNATSHR | |
| SCHEMBL22260429 | 0.79 | HTT (0.31) | HTTHSD17B10DYRK1ANPSR1 | |
| SCHEMBL22260115 | 0.79 | HTT (0.37) | HTTHSD17B10DYRK1A | |
| SCHEMBL20285954 | 0.79 | PDE2A (0.32) | HTTHSD17B10DYRK1AKDM5BLMNA | |
| SCHEMBL10297546 | 0.74 | GABRA1 (0.39) | HTTHSD17B10LMNATSHR | |
| SCHEMBL17586751 | 0.74 | RPS6KA3 (0.38) | — | |
| SCHEMBL25897502 | 0.72 | RPS6KA3 (0.31) | — | |
| SCHEMBL22870345 | 0.71 | CYP2A6 (0.34) | LMNATSHR | |
| SCHEMBL15187512 | 0.71 | FAAH (0.30) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | HTT 3084/4885HSD17B10 1341/4885DYRK1A 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.